Compare HOOD & REGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | HOOD | REGN |
|---|---|---|
| Founded | 2013 | 1988 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Computer Software: Prepackaged Software | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 78.6B | 68.6B |
| IPO Year | 2021 | 1995 |
| Metric | HOOD | REGN |
|---|---|---|
| Price | $113.78 | $670.06 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 23 | 25 |
| Target Price | $105.00 | ★ $830.16 |
| AVG Volume (30 Days) | ★ 29.6M | 986.6K |
| Earning Date | 04-28-2026 | 04-29-2026 |
| Dividend Yield | N/A | ★ 0.55% |
| EPS Growth | ★ 31.41 | 8.19 |
| EPS | 0.38 | ★ 6.75 |
| Revenue | $4,473,000,000.00 | ★ $5,872,227,000.00 |
| Revenue This Year | $21.75 | $12.45 |
| Revenue Next Year | $19.35 | $10.13 |
| P/E Ratio | $309.38 | ★ $96.34 |
| Revenue Growth | ★ 51.58 | 20.82 |
| 52 Week Low | $63.52 | $541.00 |
| 52 Week High | $153.83 | $821.11 |
| Indicator | HOOD | REGN |
|---|---|---|
| Relative Strength Index (RSI) | 65.60 | 64.23 |
| Support Level | $105.65 | $668.85 |
| Resistance Level | $122.62 | $783.87 |
| Average True Range (ATR) | 7.13 | 15.22 |
| MACD | 1.22 | 8.25 |
| Stochastic Oscillator | 78.17 | 99.63 |
Robinhood is a diversified financial services provider best known for its retail brokerage platform, which historically caters to a young, risk-seeking clientele that trades heavily on margin and in higher-risk asset classes like options, futures, cryptocurrencies, and more recently, in prediction markets. As those customers' financial needs have begun to mature, Robinhood has rolled out a suite of more conventional products, from retirement accounts to high-yield cash sweep accounts to nascent advisory services (Robinhood Strategies). With $322 billion in customer assets and 27 million active accounts at year-end 2025, the firm has emerged as a significant player in the large and quickly growing US brokerage market.
Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including low-dose Eylea and Eylea HD, approved for wet age-related macular degeneration and other eye diseases; Dupixent in immunology; Praluent for LDL cholesterol lowering; Libtayo in oncology; Kevzara in rheumatoid arthritis; and Lynozyfic for multiple myeloma. Regeneron has multiple partnerships and collaboration agreements, with Sanofi (Dupixent, others) and Bayer (Eylea) as its largest partners.